MG
TARA icon

Marex Group’s Protara Therapeutics TARA Stock Holding History

Marex Group’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Sell
35,250
-20,000
-36% -$95.1K ﹤0.01% 1046
2026
Q1 		$288K Sell
55,250
-30,000
-35% -$178K ﹤0.01% 791
2025
Q4 		$454K Buy
85,250
+63,000
+283% +$350K ﹤0.01% 596
2025
Q3 		$96.8K Buy
+22,250
New +$72K ﹤0.01% 778

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Marex Group's TARA Position: Q2 2026 in Review

Marex Group reduced its Protara Therapeutics (TARA) stake by 36% in Q2 2026, selling an estimated $95.1K and leaving 35,250 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

Marex Group first reported a position in TARA in Q3 2025 and has held it in 4 quarters since. The position peaked at $454K in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Marex Group held 35,250 shares of Protara Therapeutics worth $135K as of Q2 2026.
  • Marex Group sold 20,000 Protara Therapeutics shares in Q2 2026, an estimated $95.1K.
  • Protara Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #1046 holding.
  • Marex Group first reported a position in Protara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Marex Group's Protara Therapeutics position peaked at $454K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.